Emerging Stocks Down Under 7 June 2022: Polynovo (ASX:PNV)

Polynovo: The pandemic has only delayed its dreams, not ended them

Capped at over $820m and up nearly 500% in five years, Polynovo (ASX: PNV) has been one of the ASX’s most prominent Biotechs. Its NovoSorb technology has been commercialised but has barely reached its full potential. Polynovo’s path has not been without setbacks and investors have punished the company in the past year. But if market conditions return to normal, we believe there is a significant opportunity for the company to capture.

Click here to read the previous edition of Emerging Stocks Down Under published 31 May 2022

For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.